Trial NCT02626455

View at ClinicalTrials.gov 
Org. Study IDs: 17833
Secondary IDs: 2015-001088-38

Last trial update was posted on 2023-12-01

MeSH Interventions

Bendamustine Hydrochloride Cyclophosphamide Doxorubicin Prednisone Rituximab Vincristine

MeSH Conditions

Lymphoma Lymphoma, Non-Hodgkin

Other Conditions


Stopping Reasons

The study did not meet the primary endpoint. The addition of copanlisib to standard immunochemo therapy did not improve progression-free survival compared to the control arm. Base on the study results, company decided to terminate the study.

Limitations And Caveats

N/A

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID